Together with the fact that DW0254 compound sensitivity did not correlate with RAS mutational status alone of acute leukemia cell lines, this suggests that RAS/AKT/RAC pathway activation might be a better predictor of response to PDE6D inhibitors. Here, PDE6D is linked to acute leukemia.